Falk Symposium: An Update on SNMC (Stronger Neo-Minophagen C). In honour of Hans Popper's 100th birthday

Hiyashi, N.; Manns, M.P.

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.

Details

Published by: Springer

Publication Date: 2004-07-21

Format: Hardcover

ISBN-13: 9780792387961

DOI:

Dimensions: 235cm x155cm

Pages: 130